Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Gastroesophageal Cancer
How would you treat a patient with adenocarcinoma of the GE junction in the setting of interstitial lung disease?
Is neoadjuvant chemoradiation or perioperative chemotherapy preferred?
Answer from: Radiation Oncologist at Academic Institution
Protons.
Sign in or Register to read more
6623
Related Questions
How was treatment response assessed on the PROSPECT trial?
For anal radiation dermatitis, does anyone have experience with 3M Cavilon protectant?
For a patient who has T4 squamous cell esophageal carcinoma on imaging, and who has biopsy-confirmed disease in an involved local lymph node, are EUS or EGD still indicated to complete workup?
Would you offer pelvic re-irradiation in the setting of locally recurrent anal cancer in the presacral region?
Would 45 Gy to the pelvis be sufficient for a locally advanced rectal cancer that has a complete metabolic response to TNT?
What dose constraints and how much CTV do you extend into stomach for a patient with a GEJ tumor being treated with pre-operative or definitive chemo-RT?
Would you include the entire bladder in the treatment field of a patient with a history of T1 bladder cancer s/p intravesical therapy who is now being planned for chemoradiation for a T3N1 rectal cancer?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?